<DOC>
	<DOCNO>NCT02755064</DOCNO>
	<brief_summary>With study , investigator hop learn rate food empty stomach affect blood sugar value . Using data study , hope improve ability control blood sugar individual type 1 diabetes mellitus .</brief_summary>
	<brief_title>Relationship Between Gastric Emptying Glycemic Variability Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The study comprise 3 outpatient visit period 11 day . Safety lab test perform screen visit . At visit , GE evaluate 13C-spirulina breath test . Phase 1 : After baseline assessment ( GE1 ) , second third GE test perform treatment intravenous ( GE2 ) oral erythromycin ( GE3 ) placebo . Subject arrive fasting study visit . Prior gastric emptying study , placement intravenous line . Subject continue take insulin medication usual . Subjects require finger-stick glucose reading 4 time day instruct physician . Subjects provide log sheet keep track meal time , insulin dose time , glucose reading , activity . Continuous glucose monitoring ( CGM ) gastric empty evaluate duration study ( 11 day ) thrice respectively . GE evaluate baseline ( GE1 ) randomize intravenous saline , erythromycin ( 2 mg/kg ) erythromycin ( 3 mg/kg ) . Phase 2 : Thereafter , patient randomize erythromycin ethyl succinate suspension ( 250 mg tid ) placebo total period 7 day . GE3 preferably perform day 7 , oral erythromycin placebo start . An EKG perform baseline identify ( exclude ) patient contraindication erythromycin . An EKG also repeat end study , i.e. , GE3 safety . No change insulin ( apart patient self management skill ) medication make research study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Erythromycin lactobionate</mesh_term>
	<criteria>Healthy male nonpregnant nonbreastfeeding female volunteer type 1 diabetes mellitus ( T1 DM ) undergo clinicallyindicated continuous glucose monitoring ( CGM ) study ( Women childbearing potential may enrol use contraceptive throughout length study ) . Able provide write informed consent participate study Able communicate adequately investigator comply requirement entire study . Glycated hemoglobin ( A1c ) &lt; 8.5 % Severe nausea vomit preclude study assessment Use medication alter GI motility e.g. , narcotic , medication significant anticholinergic effect , CYP450 3A4 inhibitor , antibiotic ( experimental drug erythromycin ) , pramlintide GLP1 base therapy . Subjects use metoclopramide erythromycin enrol medication hold 7 day CGM1 GE1 Pancreas transplantation Contraindications erythromycin : i.e. , 1 ) concomitant therapy astemizole , cisapride , pimozide , terfenadine ; 2 ) hypersensitivity erythromycin component product ; Corrected QT interval EKG &gt; 460 msec Known family history sudden death congenital QT prolongation Serum potassium magnesium level outside normal range screen visit 1 Patients moderate severe renal insufficiency , i.e. , subject eGFR &lt; 60 mL/min/1.73 m^2 ) Patients allergic egg , wheat milk unwilling consume product .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>